Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jan 1;84(1):19–24. doi: 10.1054/bjoc.2000.1539

A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer

P W M Johnson 1, M F Muers 2, M D Peake 3, K M Poulter 4, E M Gurney 4, V Napp 4, P M Hepburn 4, J M Brown 4
PMCID: PMC2363622  PMID: 11139307

Abstract

A randomized trial was conducted to determine whether administration of Amifostine with chemotherapy for small cell lung cancer could decrease the toxicity. 84 patients with small cell lung cancer of favourable prognosis (limited disease, performance status 0–1; limited disease with performance status 2 but normal sodium and alkaline phosphatase, or extensive diseas with performance status 0–1, normal sodium and alkaline phosphatase) received treatment with Ifosfamide 3 g/m2intravenously, Carboplatin (Glomerular filtration rate + 25) ×6 mg intravenously, Etoposide 50 mg orally, twice daily, for 7 days, every 3 weeks. Patients were randomized to receive amifostine 740 mg/m2immediately prior to the intravenous drugs (n = 42) or to receive chemotherapy alone (n = 42). The two groups were similar with respect to baseline prognostic factors. There was no significant difference in the occurrence of grade III or IV neutropenia or thrombocytopenia between the two groups, nor in the response rate or overall survival, for which the median was 11 months in the chemotherapy only group and 14 months in the group treated with amifostine. This study has not shown a protective effect from the use of amifostine with this regimen and there does not appear to be any effect upon the efficacy of treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: small cell lung cancer, chemotherapy, myelotoxicity, chemoprotection, amifostine, survival

Full Text

The Full Text of this article is available as a PDF (63.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Glover D., Glick J. H., Weiler C., Hurowitz S., Kligerman M. M. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol. 1986 Apr;4(4):584–588. doi: 10.1200/JCO.1986.4.4.584. [DOI] [PubMed] [Google Scholar]
  2. Miles D. W., Fogarty O., Ash C. M., Rudd R. M., Trask C. W., Spiro S. G., Gregory W. M., Ledermann J. A., Souhami R. L., Harper P. G. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol. 1994 Jan;12(1):77–82. doi: 10.1200/JCO.1994.12.1.77. [DOI] [PubMed] [Google Scholar]
  3. Prendiville J., Lorigan P., Hicks F., Leahy B., Stout R., Burt P., Thatcher N. Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. Eur J Cancer. 1994;30A(14):2085–2090. doi: 10.1016/0959-8049(94)00363-a. [DOI] [PubMed] [Google Scholar]
  4. Roth B. J., Johnson D. H., Einhorn L. H., Schacter L. P., Cherng N. C., Cohen H. J., Crawford J., Randolph J. A., Goodlow J. L., Broun G. O. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992 Feb;10(2):282–291. doi: 10.1200/JCO.1992.10.2.282. [DOI] [PubMed] [Google Scholar]
  5. Shevlin P. M., Muers M. F., Peake M. D., Hosker H. S., Stead M. L., Poulter K. M., Brown J. M. Modified ice study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer. Lung Cancer. 1998 Aug;21(2):115–126. doi: 10.1016/s0169-5002(98)00035-x. [DOI] [PubMed] [Google Scholar]
  6. Souhami R. L., Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990 Apr;61(4):584–589. doi: 10.1038/bjc.1990.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Steward W. P., von Pawel J., Gatzemeier U., Woll P., Thatcher N., Koschel G., Clancy L., Verweij J., de Wit R., Pfeifer W. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol. 1998 Feb;16(2):642–650. doi: 10.1200/JCO.1998.16.2.642. [DOI] [PubMed] [Google Scholar]
  8. Thatcher N., Girling D. J., Hopwood P., Sambrook R. J., Qian W., Stephens R. J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol. 2000 Jan;18(2):395–404. doi: 10.1200/JCO.2000.18.2.395. [DOI] [PubMed] [Google Scholar]
  9. Yuhas J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980 May;40(5):1519–1524. [PubMed] [Google Scholar]
  10. van der Vijgh W. J., Peters G. J. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin Oncol. 1994 Oct;21(5 Suppl 11):2–7. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES